New Listing News | Sino Medical Sciences Technology Inc. (688108.SH) plans to list on the Hong Kong Stock Exchange. The China Securities Regulatory Commission requires additional information on changes in share capital and shareholders, etc.

On July 3rd, the China Securities Regulatory Commission released the "Requirements for Supplementary Materials for Overseas Issuance and Listing Registration (June 29, 2026 - July 3, 2026)." The International Department of the China Securities Regulatory Commission issued supplementary material requirements for 7 companies. Among them, Sino Medical Sciences Technology Inc. was required to provide detailed explanations of the company's establishment and changes in share capital and shareholders since its establishment, including but not limited to capital increase, share transfer, and related payment information. According to the disclosure by the Hong Kong Stock Exchange on May 27th, Sino Medical Sciences Technology Inc. has submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with CMB International as the sole sponsor. The China Securities Regulatory Commission requested Sino Medical Sciences Technology Inc. to provide supplementary explanations on the following matters, and to have lawyers verify and provide clear legal opinions: 1. Please explain: In accordance with the "Regulatory Rules Application Guidelines - Overseas Issuance and Listing Class No. 2: Guidelines for Content and Format of Filing Materials," provide detailed explanations of the company's establishment and changes in share capital and shareholders since its establishment, including but not limited to capital increase, share transfer, and related payment information; Lawyers should review and provide opinions on whether there are any related relationships between shareholders, whether there are instances of entrusted shareholding or other interest transfers, and whether the establishment and various changes in equity of the issuer are legal and compliant. 2. Please explain: The specific fulfillment of regulatory procedures related to overseas investments and foreign exchange registrations involving the establishment of your company's overseas subsidiaries, and provide a conclusive opinion on compliance. 3. Please explain: Whether the participants in the employee stock incentive plan are employees of the company, the specific composition and positions of the participants, whether there are any relationships between the participants and other shareholders, directors, supervisors, or senior management personnel of the issuer; whether there are external personnel, if so, provide verification and explanations according to the requirements of the "Regulatory Rules Application Guidelines - Overseas Issuance and Listing Class No. 2" regarding external personnel; whether participants holding incentive shares after leaving the company comply with the previous agreements, whether there are disputes or potential disputes; the share subscription price and fairness of the stock incentive plan, reasons and backgrounds of external personnel's share subscription, subscription price, valuation basis, and source of funds, if the subscription price is the same or close to that of employees, explain whether there are any interest transfers; and provide clear conclusive opinions on the legality and compliance of implemented stock incentive plans and option incentive plans after listing. 4. Please explain: The basis for identifying your company's controlling shareholder and ultimate controlling person, and provide reasons and rationale based on the shareholding proportions of each shareholder. 5. Please explain: Whether your company and its subsidiaries' business scope and actual operations involve restrictions or prohibitions on foreign investment in the "Special Management Measures for Foreign Investment Access (Negative List) (2024 Edition)," and whether they will continue to meet the requirements for foreign investment access after this listing. 6. Please explain: Whether your company's actual operations involve advanced brain-computer interface technology and provide specific details. The prospectus shows that Sino Medical Sciences Technology Inc. (688108.SH) is a global interventional medical equipment company based on independent research and internal innovation, dedicated to addressing major unmet clinical needs and providing treatments with curative intentions that have been clinically validated. The company was founded in 2007, headquartered in Tianjin, and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 30, 2019. Sino Medical Sciences Technology Inc.'s product portfolio mainly covers two major areas: coronary artery intervention and neurovascular intervention, and has established a leading innovative product line in the industry. The company has successfully commercialized 26 products, including 24 Class III medical devices. In the coronary field, its core product, the HT Supreme drug-eluting stent system, is the first drug-eluting stent system developed by a Chinese company and approved for market in Europe. According to the prospectus, the company has established 11 core technology platforms and a global intellectual property portfolio, with products being used in over 3,000 hospitals worldwide.